Reprogrammable RNA therapies for regeneration and longevity.
RNARevive is a science-driven biotech developing reprogrammable RNA therapeutics to restore function and support longevity at the molecular and cellular level.
We are a science-driven biotech developing durable RNA therapeutics in Canada.
RNARevive is building a next-generation reprogrammable RNA therapeutics platform for longevity and regenerative medicine. We believe RNA can help the body repair itself and restore function by acting at the molecular and cellular level. If you’re looking for durable therapies that reduce dosing burden and improve patient outcomes, you’re in the right place. Our platform is designed to be scalable, adaptable across multiple indications, and engineered for real-world clinical translation.
Our Programs
OsteoRevive™
(Bone Regeneration)
Self-amplifying RNA designed to regenerate bone by reprogramming local cells and restoring osteogenic function.
DenosRevive™
(Durable Anti-RANKL)
A next-generation RNA approach to replace frequent biologic dosing with long-lasting therapeutic protein expression.
Anti-VGFRevive™
(Eye Disease)
A durable RNA-based alternative to repeated anti-VEGF injections for retinal diseases, with fewer administrations per year.
Gallery
Our Team
Mardin Fallah
Mardin is the Founder and CEO of RNARevive, a biotechnology company developing self-amplifying RNA therapies designed to deliver longer-lasting treatments with fewer administrations. With a background in regenerative medicine and RNA engineering, his work focuses on translating breakthrough science into scalable medicines for age-related and complex diseases.
Nina Karpoff
Nina brings a strong mix of biotech strategy, partnerships, and execution to RNARevive. She helps shape our business direction, builds key relationships across the ecosystem, and supports the long-term growth of the company — ensuring our science is translated into a real product that can reach patients.
Peter Kannu, MD, PhD
Peter is a physician-scientist specializing in bone health and rare skeletal disorders. At RNARevive, he guides clinical strategy and translational development, ensuring our RNA-based therapies are designed with real patient needs in mind and aligned with future clinical and regulatory pathways.
Why Us?
Durable Expression
Durable Expression Our self-amplifying RNA platform enables longer-lasting therapeutic protein production from a single administration.
Lower Dose, Better Efficiency
saRNA requires significantly lower doses than conventional mRNA, improving manufacturability and reducing treatment burden.
Designed for Translation
Built with clinical, regulatory, and real-world delivery in mind—starting with age-related bone loss and tissue regeneration.
Our belief
We believe no patient should suffer simply because current therapies are too burdensome, too expensive, or too difficult to deliver.
Our technology
Instead of manufacturing therapeutic proteins outside the body, we deliver a temporary RNA instruction that enables a patient’s own cells to produce the medicine.
The RNA provides the recipe, works for a defined period, and then naturally degrades.
Our Address
Enterprise Square, 103 St NW, Edmonton, AB T5J 0B2